216 filings
8-K
NVCR
NovoCure Ltd
20 May 24
Regulation FD Disclosure
8:01am
10-Q
2024 Q1
NVCR
NovoCure Ltd
Quarterly report
2 May 24
7:01am
8-K
NVCR
NovoCure Ltd
2 May 24
Novocure Reports First Quarter 2024 Financial Results
7:01am
DEFA14A
NVCR
NovoCure Ltd
22 Apr 24
Additional proxy soliciting materials
4:02pm
DEF 14A
NVCR
NovoCure Ltd
Definitive proxy
22 Apr 24
4:00pm
8-K
pnghcacx556l0s14
27 Mar 24
Regulation FD Disclosure
7:00am
S-8
2j748l pbpswdpqqa56i
22 Feb 24
Registration of securities for employees
7:11am
8-K
xmom9mpj8o7tv9c
22 Feb 24
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
7:06am
8-K
lsvab9nj rbmfbjgm3
18 Jan 24
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
7:01am
8-K
ws20xarz
9 Jan 24
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
7:00am
8-K
4d3tg31m
8 Jan 24
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
7:10am
8-K
aw5nl3qmle
4 Jan 24
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
4:10pm
8-K
c2k7xig4
28 Nov 23
Regulation FD Disclosure
7:30am
8-K
zxe8luc0klou2 xvk98
26 Oct 23
Novocure Reports Third Quarter 2023 Financial Results
7:03am
8-K
lh90j
28 Aug 23
Regulation FD Disclosure
7:00am
8-K
lvj09 q1kaccvjy0
27 Jul 23
Novocure Reports Second Quarter 2023 Financial Results
7:03am